Clinical effectiveness and costeffectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review and economic evaluation

Health Technology Assessment

Volumn 17, Issue 31, 2013, Pages 1-277

  Brown, T ^a   Pilkington, G ^a   Bagust, A ^a   Boland, A ^a   Oyee, J ^a   Tudur Smith, C ^a   Blundell, M ^a   Lai, M ^a   Martin Saborido, C ^a   Greenhalgh, J ^a   Dundar, Y ^a   Dickson, R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ABDOMINAL PAIN; ACNE; ACUTE HEART INFARCTION; ADVANCED CANCER; ADVERSE OUTCOME; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BLEEDING DISORDER; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HAIR LOSS; HEARING DISORDER; HEART DISEASE; HUMAN; HYPONATREMIA; INFECTION; INJECTION SITE REACTION; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PARONYCHIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMONIA; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEAKNESS; WEIGHT REDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; LUNG NEOPLASMS; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84881061948     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17310     Document Type: Article

References (159)

1. Cancer Research UK. CancerStats: lung cancer and smoking-key facts. URL: http://info. cancerresearchuk.org/cancerstats/types/lung/ (cited January 2011).
2. Mackenbach J, Huisman M, Andersen O, Bopp M, Borgan J, Borrell C, et al. Inequalities in lung cancer mortality by the educational level in 10 European populations. Eur J Cancer 2004;40:126-35. http://dx.doi.org/10.1016/j.ejca.2003.10.018
3. Pugh H, Power C, Goldblatt P, Arber S. Women's lung cancer mortality, socio-economic status and changing smoking patterns. Soc Sci Med 1991;32:1105-10. http://dx.doi. org/10.1016/0277-9536(91)90086-R
4. Pollock AM, Vickers N. Breast, lung and colorectal cancer incidence and survival in South Thames Region, 1987-1992: the effect of social deprivation. J Pub Health Med 1997;19:288-94. http:// dx.doi.org/10.1093/oxfordjournals.pubmed.a024632
5. Cancer Research UK. CancerHelp UK, statistics and outlook for lung cancer. 2011. URL: www. cancerhelp.org.uk/type/lung-cancer/treatment/statistics-and-outlook-for-lung-cancer#outcome (cited February 2011).
6. Cancer Research UK. CancerHelp UK, lung cancer risks and causes. URL: www. cancerhelp.org.uk/ type/lung-cancer/about/lung-cancer-risks-and-causes (cited February 2011).
7. National Institute for Health and Care Excellence (NICE). The diagnosis and treatment of lung cancer CG 121. 2011. URL: www. nice.org.uk/nicemedia/live/13465/54199/54199.pdf (cited February 2011).
8. The NHS Information Centre. National Lung Cancer Audit Information sheet (audit period 2008). 2009. URL: www. ic.nhs.uk/canceraudits/lung (cited July 2012).
9. Union for International Cancer Control. TNM classification of malignant tumours. London: Wiley-Blackwell; 2009.
10. Cancer Research UK. CancerHelp UK, performance status. URL: www. cancerhelp.org.uk/aboutcancer/ cancer-questions/performance-status (cited February 2011).
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. http://dx.doi. org/10.1097/00000421-198212000-00014
12. The Information Centre for Health and Social Care. National Lung Cancer Audit: key findings about the quality of care for people with lung cancer in England and Wales. Report for the audit period 2006. 2007. URL: www. ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/auditreports/ lung-cancer (cited July 2012).
13. National Institute for Health and Care Excellence (NICE). Final appraisal determination: pemetrexed for first-line treatment of non-small cell lung cancer. 2009. URL: www. nice.org.uk/nicemedia/pdf/ FADPemetrexedLungCancer.pdf (cited July 2012).
14. The NHS Information Centre. National Lung Cancer Audit, report for the audit period 2008. 2009. URL: www. royalsurrey.nhs.uk/Default.aspx?DN=c29e1a74-6b75-4201-9f9d-9745981b7d7a (cited July 2012).
15. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Eng J Med 2009;361:947-57. http://dx.doi. org/10.1056/NEJMoa0810699
16. National Institute for Health and Care Excellence (NICE). Final Appraisal Determination: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. 2010. URL: http://guidance.nice.org.uk/TA/Wave10/21/FAD/FinalAppraisalDetermination/pdf/English (cited July 2012).
17. Rossell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Eng J Med 2009;361:958-67. http://dx.doi. org/10.1056/NEJMoa0904554
18. National Collaborating Centre for Acute Care. Diagnosis and treatment of lung cancer. London: National Institute for Health and Clinical Excellence; 2005. URL: http://guidance.nice.org.uk/CG24 (cited January 2011).
19. National Institute for Health and Care Excellence (NICE). Lung cancer (non-small cell)-pemetrexed (maintenance)-Final Appraisal Determination. 2010. URL: www. nice.org.uk/guidance/index. jsp?action=download&o=48303 (cited July 2012).
20. National Institute for Health and Care Excellence (NICE). Lung cancer (non-small cell)-erlotinib: guidance. 2008. URL: http://guidance.nice.org.uk/TA162 (cited July 2012).
21. National Institute for Health and Care Excellence (NICE). Lung cancer (non-small-cell, advanced or metastatic maintenance treatment)-erlotinib (monotherapy): appraisal consultation document. 2011. URL: www. nice.org.uk/guidance/index.jsp?action=article&o=51743 (cited February 2011).
22. National Institute for Health and Care Excellence (NICE). NICE guidance by topic-cancer. 2009. URL: www. nice.org.uk/guidance/index.jsp?action=byTopic&o=7178 (cited September 2009).
23. Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, et al. Pemetrexed for maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): a Single Technology Appraisal. Liverpool: Liverpool Reviews and Implementation Group (LRiG), The University of Liverpool; 2009.
24. Cancer Research UK. Lung cancer-UK incidence statistics. URL: http://info.cancerresearchuk.org/ cancerstats/types/lung/incidence/ (cited January 2011).
25. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9. http://dx.doi.org/10.1016/S1470-2045(10)70112-1
26. National Institute for Health and Care Excellence (NICE). NICE technology appraisal guidance 181. Pemetrexed for the first-line treatment of non-small-cell lung cancer. 2009. URL: www. nice.org.uk/ nicemedia/live/12243/45501/45501.pdf (cited July 2012).
27. National Institute for Health and Care Excellence (NICE). NICE technology appraisal guidance 192. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. 2010. URL: http://guidance.nice.org.uk/TA192/Guidance/pdf/English (cited July 2012).
28. Wang J, Wu N, Cham M, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. Am J Roentgenol 2009;193:1090-6. http://dx.doi.org/10.2214/AJR.08.1367
29. Aaronson N, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. http://dx.doi.org/10.1093/jnci/85.5.365
30. Bergman B, Aaronson N, Ahmedzai S. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 1994;30:635-42. http://dx.doi. org/10.1016/0959-8049(94)90535-5
31. Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996;23:31-40.
32. Cella D, Bonomi A, Lloyd S, Tulsky D, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220. http://dx.doi.org/10.1016/0169-5002(95)00450-F
33. Grutters J, Joore M, Wiegman E, Langendijk J, de Ruysscher D, Hochstenbag M. Health-related quality of life in patients surviving non-small cell lung cancer. Thorax 2010;65:903-7. http://dx.doi. org/10.1136/thx.2010.136390
34. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Loper P, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-80. http://dx.doi.org/10.1093/jnci/92.13.1074
35. Bischoff HG, Anderson H, Arellano J, van den Borne B, Langer F, Leschinger MI, et al. Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries. 2007. URL: http://ers-education.org/media/2007/eposters/blogs-3571.html (cited July 2011).
36. Eli Lilly. Lilly reports third-quarter 2010 results. URL: https://investor.lilly.com/releasedetail2. cfm?ReleaseID=521145 (cited February 2011).
37. Espicom Business Intelligence Ltd. Cancer drug discoveries: what the future holds: non-small cell lung cancer chapter. 2009. URL: www. researchandmarkets.com/reportinfo.asp?report_ id=568643&t=t&cat_id= (cited February 2011)
38. British National Formulary. URL: www. bnf.org/bnf/index.htm (cited May 2011).
39. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in nonsmall-cell lung cancer. Health Technol Assess 2001;5(32).
40. Moher D, Liberati A, Tetzlaff J, Altman D, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. BMJ 2009;339:332-9. http://dx.doi. org/10.1136/bmj.b2535
41. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technol Assess 2003;7(34).
42. Centre for Reviews and Dissemination. Centre for Reviews and Dissemination's guidance for undertaking reviews in health care. 2009. URL: www. york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf (cited July 2012).
43. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91. http://dx.doi.org/10.1200/JCO.2002.02.068
44. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24. http://dx.doi.org/10.1200/JCO.2003.12.046
45. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-34. http://dx.doi. org/10.1200/JCO.2003.06.099
46. Smit EF, van Meerbeeck JPAM, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909-17. http:// dx.doi.org/10.1200/JCO.2003.03.195
47. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002;346:92-8. http://dx.doi.org/10.1056/NEJMoa011954
48. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-18.
49. Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179-89. http://dx.doi.org/10.1016/ S0169-5002(02)00444-0
50. Chang J, Tsao T, Yang C, Lin M, Cheung Y, Liaw C, et al. A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer. Chang Gung Med J 2008;31:559-66.
51. Chen YM, Perng RP, Shih JF, Lee YC, Lee CS, Tsai CM, et al. A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer 2004;90:359-65. http://dx.doi.org/10.1038/sj.bjc.6601526
52. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007;56:363-9. http://dx.doi.org/10.1016/j.lungcan.2007.01.011
53. Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, et al. Sequential twoline strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 2005;16:81-9. http://dx.doi.org/10.1093/annonc/mdi013
54. Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41:81-92. http://dx.doi.org/10.1016/j.ejca.2004.08.029
55. Helbekkmo N, Sundstrom SH, Aasebo U, Fr Brunsvig P, Von Plessen C, Hjelde HH, et al. Vinorelbine/ carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283-9. http://dx.doi.org/10.1038/sj.bjc.6603869
56. Langer CJ, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418-23. http:// dx.doi.org/10.1200/JCO.2005.04.9452
57. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 2007;18:317-23. http://dx.doi.org/10.1093/annonc/mdl377
58. Thomas P, Robinet G, Gouva S, Fournel P, Lena H, Le Caer H, et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer. GFPC 99-01 study (Groupe Francais de Pneumo-cancerologie). Lung Cancer 2006;51:105-14. http://dx.doi.org/10.1016/j.lungcan.2005.10.004
59. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, et al. Global lung oncology branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009;20:1249-56. http://dx.doi.org/10.1093/annonc/ mdn774
60. Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 2010;21:540-7. http://dx.doi.org/10.1093/annonc/mdp352
61. Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51. http:// dx.doi.org/10.1200/JCO.2007.15.0375
62. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24. http://dx.doi.org/10.1200/JCO.2008.20.9114
63. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med 2010;362:2380-8. http://dx.doi.org/10.1056/NEJMoa0909530
64. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-smallcell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74. http://dx.doi.org/10.1200/ JCO.2010.33.4235
65. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. http://dx.doi.org/10.1016/S1470-2045(09)70364-X
66. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. http://dx.doi.org/10.1002/ (SICI)1097-0258(19981230)17:24(2815::AID-SIM11023.0.CO;2-8
67. Williamson P, Smith C, Hutton J, Marson A. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-51. http://dx.doi.org/10.1002/sim.1303
68. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. http://dx.doi.org/10.1002/sim.1186
69. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. http://dx.doi.org/10.1136/bmj.327.7414.557
70. Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. http://dx.doi.org/10.1002/sim.1875
71. Caldwell D, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. http://dx.doi.org/10.1136/bmj.331.7521.897
72. Multi-parameter Evidence Synthesis Research Group. Formal methods for multi-parameter evidence synthesis and their role in epidemiology and economic evaluation. URL: www. bristol.ac.uk/cobm/ research/mpes (cited July 2012).
73. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55.
74. Tsai CM WG, Su WJ, Chen YM, Chiu CH, Chiang SC, Perng RP. Randomized phase II study of cisplatin/vinorelbine vs. cisplatin/gemcitabine vs. vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22.
75. Kawahara M KK, Yoshioka H, Kawasaki M, Fujita Y, Yonei T, Ogushi F, et al. Randomized phase II study of carboplatin plus either docetaxel (CbD) or paclitaxel (CbP) in Japanese patients with advanced non-small cell lung cancer (NSCLC): JMTO LC07-01. J Clin Oncol 2010;28.
76. Huang CH, Langer CJ, Minniti JC, Nahum K, Seldomridge J, Hutter B, et al. Phase III toxicity trial of carboplatin (Cb) plus either docetaxel (D) or paclitaxel (P) in advanced non-small cell lung cancer (NSCLC): preliminary findings of OPN-001. Proc Am Soc Clin Oncol 2002;21.
77. McNeil C. Negative data from lung cancer trial may change practice guidelines, study designs. J Natl Cancer Inst 2006;98:1518-20. http://dx.doi.org/10.1093/jnci/djj459
78. Office for National Statistics. Cancer Statistics Registrations. Office for National Statistics; 2008. MB1 39. URL: www. statistics.gov.uk/downloads/theme_health/mb1-39/mb1-no39-2008.pdf (cited July 2011).
79. Le Chevalier T, Scagliotti G, Natalec R, Dansond S, Roselle R, Stahelf R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced nonsmall-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80. http:// dx.doi.org/10.1016/j.lungcan.2004.10.014
80. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: clinical trial endpoints for the approval of cancer dugs and biologics. 2007. URL: www. fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (cited July 2011).
81. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 2009. URL: www. recist.com/ (cited February 2011).
82. Ou S, Ziogas A, Zell J. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-93. http://dx.doi.org/10.1097/JTO.0b013e3181b27b15
83. Billingham L, Gaunt P, Jarrett HW, Dunlop D, Thompson J, O'Byrne KJ, et al. Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. Thorax 2011;66:S86. http://dx.doi.org/10.1136/thoraxjnl-2011-201054b.86
84. Ardizzoni AL, Boni L, Tiseo M, Fossella F, Schiller J, Paesmans M, et al. Cisplatin-versus carboplatinbased chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57. http://dx.doi.org/10.1093/jnci/ djk196
85. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57:348-58. http://dx.doi.org/10.1016/j.lungcan.2007.03.014
86. Ferry D, Billingham L, Jarrett H, Dunlop D, Thompson J, Kumar M, et al. British Thoracic Oncology Group Trial, BTOG2: randomised phase III clinical trial of gemcitabine (1250 mg/m2) combined with cisplatin 50 mg/m2 (GC50) versus cisplatin 80 mg/m2 (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC. National Cancer Research Institute, 7th NCRI Cancer Conference; Liverpool 2011.
87. National Cancer Intelligence Network. Using information to improve quality & choice. 2010. URL: www. ncin.org.uk/home.aspx (cited July 2011).
88. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 2001;6:4-7. http://dx.doi. org/10.1634/theoncologist.6-suppl_1-4
89. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-72. http://dx.doi. org/10.1093/jnci/95.5.362
90. Peake M, Thompson S, Lowe D, Pearson M, centres Obotp. Ageism in the management of lung cancer. Age Aging 2003;32:171-7. http://dx.doi.org/10.1093/ageing/32.2.171
91. Beckett P, Woolhouse I, Peake M, Stanley R, Harrison R. P215 The influence of age on management of lung cancer patients in England. Thorax 2010;65:A167-A8. http://dx.doi.org/10.1136/ thx.2010.151068.16
92. Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM, et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002;13:108-15. http://dx.doi.org/10.1093/annonc/mdf009
93. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002;57:20-8. http://dx.doi.org/10.1136/thorax.57.1.20
94. Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy symptomatic advanced nonsmall cell cancer. Eur Respir J 2006;27:895-901.
95. Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009;4:1404-14. http://dx.doi.org/10.1097/JTO.0b013e3181ba31e0
96. Le Lay K, Myon E, Hill S, Riou-Franca L, Scott D, Sidhu M, et al. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007;8:145-51. http://dx.doi.org/10.1007/s10198-006-0034-1
97. Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of non-small cell lung cancer. Pharmacoeconomics 2002;20:325-37. http://dx.doi. org/10.2165/00019053-200220050-00004
98. Lievens Y, Kesteloot K, Van den Bogaert W. CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol 2005;75:171-8. http://dx.doi.org/10.1016/j. radonc.2005.03.011
99. Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. Economic evaluation of docetaxel/ gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic nonsmall cell lung cancer in Greece. Lung Cancer 2007;58:275-81. http://dx.doi.org/10.1016/j. lungcan.2007.06.012
100. Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Prac 2010;6:12-18. http://dx.doi.org/10.1200/JOP.091058
101. Neymark N, Lianes P, Smit EF, Van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics 2005;23:1155-66. http://dx.doi.org/10.2165/00019053-200523110-00007
102. Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A, et al. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 2005;48:379-87. http:// dx.doi.org/10.1016/j.lungcan.2004.11.014
103. Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Lung Cancer 2006;52:365-71. http://dx.doi.org/10.1016/j.lungcan.2006.03.005
104. Rubio-Terres C, Luis Tisaire J, Kobina S, Moyano A. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer 2002;35:81-9. http://dx.doi.org/10.1016/ S0169-5002(01)00280-X
105. Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Economic evaluation of docetaxelgemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic nonsmall-cell lung cancer in Greece: A cost-minimization analysis. Ann Oncol 2010;21:1462-7. http://dx.doi.org/10.1093/annonc/mdp551
106. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. http://dx.doi. org/10.1136/bmj.313.7052.275
107. Medicare-Centers for Medicare & Medicaid Services (CMS). Payment allowance limits for Medicare: part B drugs effective January 1, 2008 through March 31, 2008. URL: www. cms.hhs.gov/ McrPartB DrugAvgSalesPrice/01a_2008aspfiles.asp#TopOfPage (accessed 8 January 8 2008).
108. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 40, September 2000. London: BMA and RPS; 2000.
109. Department of Health. The new NHS-2000 reference costs. URL: www. doh.gov.uk/nhsexec/ refcosts.htm (accessed 28 March 2002).
110. Netten A, Curtis L. Unit costs of health and social care 2000. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury; 2000.
111. Bagust A, Barraza-Llorens M, Philips Z. Economic evaluation of gemcitabine in the treatment of advanced non-small cell lung cancer. Stage 3: cost-effectiveness analysis. Draft final report to Eli Lilly, York Health Economics Consortium, University of York. Eli Lilly and Company Ltd; 1999.
112. College Tarieven Gezondheidszorg. Tariefboek medisch specialitsen and Bijlage bij Tarieflijst Instellingen 2002. URL: www. ctgzorg.nl (accessed September 2003).
113. College voor Zorgverzekeringen. Farmakotherapeutisch Kompas 2002. Amstelveen: Medisch Farmaceutische Voor-lichting; 2002.
114. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, et al. Clinicalbenefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12:1221-30. http://dx.doi.org/10.1023/A:1012208711013
115. Vansteenkiste J, Edelman MJ, De Marinis F, Douillard J-Y, Stahel RA, Arellano J, et al. Indirect comparison of pemetrexed plus cisplatin with other platinum based therapies for first line advanced non small cell lung cancer. International Thoracic Oncology Congress, October 1-5, 2008
116. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcome 2008;6:84. http://dx.doi.org/10.1186/1477-7525-6-84
117. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447-53. http://dx.doi.org/10.1054/bjoc.2000.1307
118. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
119. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-30.
120. Comella P. Interim analysis of a phase III trial. Triple-vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group. Oncology 2000;14:35-40.
121. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1321-9. http://dx.doi.org/10.1093/jnci/92.16.1321
122. Liverpool Reviews and Implementation Group. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). London: NICE; 2009.
123. Liverpool Reviews and Implementation Group. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). London: NICE; 2009.
124. Office for National Statistics. Death registration summary tables England and Wales 2010. URL: www. ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-227638 (cited September 2011).
125. Carlson J, Veenstra D, Ramsey S. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008;68:1105-13. http://dx.doi.org/10.2165/00003495-200868080-00007
126. Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (invite): A randomized, phase II study. J Clin Oncol 2008;26:4253-60. http://dx.doi.org/10.1200/ JCO.2007.15.0672
127. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63. http://dx.doi.org/10.1200/JCO.2006.06.1044
128. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42. http://dx.doi.org/10.1200/JCO.2009.26.1321
129. Ekhart C, de Jonge ME, Huitema ADR, Schellens JHM, Rodehuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 2006;12:6502-8. http://dx.doi.org/10.1158/1078-0432.CCR-05-1076
130. British Medical Association and Royal Pharmaceutical Society Society of Great Britain. British national formulary. No. 62, September 2011. London: BMA and RPS; 2011.
131. Electronic market information tool (eMit), Commercial Medicines Unit, Department of Health. Electronic market information tool (eMit). URL: http://cmu.dh.gov.uk/electronic-market-informationtool-emit/ (cited September 2011).
132. Department of Health. NHS reference costs 2009-2010. URL: www. dh.gov.uk/en/ Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_123459 (cited September 2011).
133. Maslove L, Gower NH, Spiro SG, Rudd RM, Stephens R, West P. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Thorax 2005;60:564-9. http://dx.doi.org/10.1136/thx.2004.039479
134. National Institute for Health and Care Excellence. Advanced breast cancer: diagnosis and treatment. 2009. URL: www. nice.org.uk/nicemedia/live/11778/43414/43414.pdf (cited July 2011).
135. Taylor D, Carter S, Marie Curie Cancer Care. Valuing choice-dying at home: a case for the more equitable provision of high quality support for people who wish to die at home. London; School of Pharmacy, University of London; 2004.
136. National Institute for Health and Care Excellence (NICE). Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. 2010. URL: www. nice.org.uk/nicemedia/ live/13110/50422/50422.pdf (cited July 2011).
137. Personal Social Services Research Unit. Unit costs of health and social care 2010. 2010. URL: www. pssru.ac.uk/uc/uc2010contents.htm (cited July 2011).
138. Doyle S, Llyod A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2008;62:374-80. http://dx.doi.org/10.1016/j.lungcan.2008.03.019
139. van den Hout W, Kramer G, Noordijk E, Leer J-W. Cost-utility analysis of short-vesrus long-course palliative radiotherapy in patients with non-small-cell ling cancer. J Natl Cancer Inst 2006;98:1786-94. http://dx.doi.org/10.1093/jnci/djj496
140. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2008. URL: www. nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 2009 June).
141. Ku GY, Haaland BA, Lopes J. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011;74:469-73. http://dx.doi. org/10.1016/j.lungcan.2011.04.008
142. European Medicines Agency. Erbitux. URL: www. ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000558/wapp/Post-authorisation/human_wapp_000145. jsp&mid=WC0b01ac058001d128 (accessed February 2011).
143. Fisher MD. Irinotecan/cisplatin versus vindesine/cisplatin versus irinotecan alone in advanced nonsmall-cell lung cancer. Clin Lung Cancer 2000;2:180-1.
144. Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: Preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer 2003;4:288-93. http://dx.doi. org/10.3816/CLC.2003.n.008
145. Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 2008;9:235-8. http://dx.doi.org/10.3816/CLC.2008.n.037
146. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, et al. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007;8:500-12. http://dx.doi. org/10.1016/S1470-2045(07)70146-8
147. Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: A phase III randomised trial. Lung Cancer 2002;37:9-14. http://dx.doi. org/10.1016/S0169-5002(01)00493-7
148. Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003;21:1767-74. http://dx.doi.org/10.1200/JCO.2003.11.005
149. Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003;21:2094-100. http://dx.doi. org/10.1200/JCO.2003.12.008
150. O'Brien MER, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, von Pawel J, et al. SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 2004;15:906-14. http://dx.doi.org/10.1093/annonc/mdh220
151. Ramalingam S, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, et al. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: Subanalysis of a randomized trial. J Thorac Oncol 2006;1:240-4.
152. Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquee L, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 2003;40:191-9. http://dx.doi.org/10.1016/ S0169-5002(02)00515-9
153. Gao Y, Shi ZQ, Cao CW, Zhu CL, Guo J. [A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer.] Ai Zheng 2005;24:985-9.
154. Lin YC, Lin Y, Lin W, Du CW, Wu MY, Li DR. [Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer.] Ai Zheng 2002;21:1359-61.
155. Liu L, Wang XW, Li L, Zhang X, Zhang WD, Yu XJ. [A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer.] Ai Zheng 2006;25:990-4.
156. Semrau S, Fietkau R. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. Strahlenther Onkol 2003;179:502-3.
157. Teng XY, Zhou NN, Su YS, Zhou ZM, Liu DG, He YJ. [Comparison of cisplatin combined with gemcitabine versus cisplatin combined with vinorelbine regimen for treatment of patients with advanced non-small cell lung cancer.] Ai Zheng 2003;22:404-6.
158. Xu S, Wang W, Liu X. [Clinical studies on the therapy of advanced non-small cell lung cancer (NSCLC) in the elderly using domestic gemcitabine in combination with carboplatin.] Chin J Clin Oncol 2006;33:35-7.
159. Zhang S, Wang J, Wang Q, Yang X, Hu F, Li X, et al. [A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer.] Chin J Lung Cancer 2008;11:110-14.